Novo Nordisk stock adds a USD 2.6 billion pipeline deal

Published on 10/06/2026 at 16:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock was last at DKK 246.40 on October 5, 2026, after a 0.94 percent daily decline. Q2 revenue reached DKK 78.49 billion.

Flatlay mit Spritze, Teststreifen, Notizbuch und Apfel auf weißem Untergrund — Novo Nordisk A/S (DK0062498333): Flatlay mit Spritze, Blutzucker-Teststreifen, Notizbuch und Apfel auf Weiß, Illustration mit AI erstellt.

Novo Nordisk stock was last at DKK 246.40 on Nasdaq Copenhagen on October 5, 2026, with the quote down 0.94 percent from the prior session. The latest pipeline catalyst is a licensing agreement for HRS-1596, an experimental once-weekly oral GLP-1 and GIP drug candidate.

Deal adds a new oral candidate

According to PR Newswire on September 29, 2026, Novo Nordisk secured exclusive rights outside mainland China, Hong Kong, Macao and Taiwan. The potential value is USD 2.6 billion, including a USD 300 million upfront payment and milestone payments.

HRS-1596 is phase I-ready and has approval in China to begin trials for weight management and type 2 diabetes. The candidate has not yet entered human testing, so the commercial value depends on development, regulatory and sales milestones.

Q2 revenue reaches DKK 78.49 billion

TradingView lists Q2 2026 revenue at DKK 78.49 billion and net income at DKK 20.99 billion. Net income was DKK 48.56 billion in Q1 2026, making the quarter-to-quarter comparison the key operating counterpoint to the pipeline investment.

The same page identifies Novo Nordisk A/S Class B as listed on Nasdaq Copenhagen under ticker NOVO_B and assigns the company the ISIN DK0062498333. Its market capitalization is listed at DKK 1.1 trillion, while the year-to-date performance is minus 25.41 percent.

Analysts see room above the stock

MarketScreener lists a Hold consensus from 25 analysts and an average target of DKK 307.56. That target lies 24.9 percent above the DKK 246.40 reference price, although the consensus range extends from the DKK 245 Deutsche Bank target to higher analyst estimates.

Deutsche Bank cut its target from DKK 265 to DKK 245 while retaining a Sell rating, according to MarketScreener. The split between the average target and the bearish individual view shows why the upcoming results remain important for the valuation debate.

Results date sets the next checkpoint

MarketScreener lists November 3, 2026, as the scheduled Q3 2026 earnings release date. Until then, investors have two measurable reference points: the DKK 246.40 share price and the DKK 1.1 trillion market capitalization.